79
Moderna’s chief medical officer has described the company’s products as “hacking the software of life” and permanently altering a person’s genetic code. If Moderna is poised to bring the first Covid-19 vaccine to market, a deeper look at his comments and his employer are warranted. More and more frequently, government officials, political pundits and self-appointed
2014
Fauci, war immer schon vollkommen korrupt, hatte schon früher enorme Skandale. MIt gefälschten Studien, unterschrieb er die Abnahme des Betrugs Medikamentes Remdesivir, von Donald Trumps: Gileads Firma, welche in der Sache mit dem Teilnehmer am Event 201: Johnson & Johsnon kooperiert.
29. Juni: Fauci Greenlight. Der 1,6 Milliarden US-Dollar teure Remdesivir-Vertrag mit Gilead Sciences Inc.
Dr. Anthony Fauci erteilte Gilead Sciences Inc. am 29. Juni 2020 das „Greenlight“.
Der von NIH-NIAID gesponserte halboffizielle Bericht der US-Regierung (22. Mai) mit dem Titel Remdesivir zur Behandlung von Covid-19 – Vorläufiger Bericht (NEJM) wurde verwendet, um eine wichtige Vereinbarung mit Gilead Sciences Inc. zu rechtfertigen.
Der Bericht wurde größtenteils vom Nationalen Institut für Allergien und Infektionskrankheiten (NIAID) unter der Leitung von Dr. Anthony Fauci und den National Institutes of Health (NIH) finanziert.
Auf der Grundlage der Ergebnisse des im NEJM veröffentlichten NIH-NIAID-Berichts kündigte das Ministerium für Gesundheit und menschliche Dienste (HHS) im Auftrag der Trump-Administration am 29. Juni eine Vereinbarung zur Sicherung großer Lieferungen des Remdesivir-Arzneimittels von Gilead Sciences Inc. an für die Behandlung von Covid-19 in Amerikas privaten Krankenhäusern und Kliniken.
Die frühere Gilead-Studie, die auf spärlichen Testergebnissen basiert, die im NEJM (10. April) veröffentlicht wurden, von 53 Fällen (und 56 Co-Autoren), wurde nicht hervorgehoben. Die Ergebnisse dieser Studie wurden von mehreren prominenten Ärzten und Wissenschaftlern in Frage gestellt.
Der von NIH-NIAID gesponserte halboffizielle Bericht der US-Regierung (22. Mai) mit dem Titel Remdesivir zur Behandlung von Covid-19 – Vorläufiger Bericht (NEJM) wurde verwendet, um eine wichtige Vereinbarung mit Gilead Sciences Inc. zu rechtfertigen.
Der Bericht wurde größtenteils vom Nationalen Institut für Allergien und Infektionskrankheiten (NIAID) unter der Leitung von Dr. Anthony Fauci und den National Institutes of Health (NIH) finanziert.
Auf der Grundlage der Ergebnisse des im NEJM veröffentlichten NIH-NIAID-Berichts kündigte das Ministerium für Gesundheit und menschliche Dienste (HHS) im Auftrag der Trump-Administration am 29. Juni eine Vereinbarung zur Sicherung großer Lieferungen des Remdesivir-Arzneimittels von Gilead Sciences Inc. an für die Behandlung von Covid-19 in Amerikas privaten Krankenhäusern und Kliniken.
Die frühere Gilead-Studie, die auf spärlichen Testergebnissen basiert, die im NEJM (10. April) veröffentlicht wurden, von 53 Fällen (und 56 Co-Autoren), wurde nicht hervorgehoben. Die Ergebnisse dieser Studie wurden von mehreren prominenten Ärzten und Wissenschaftlern in Frage gestellt.
Gekauft, von der Tamiflu Betrugs Firma des Donald Rumsfeld, testet der Chef des wegen Hgyiene Toten bekannten und berüchtigten Schwabinger Krankenhauses, auch noch den Ebola Müll: Remdesivir, mit Menschenversuchen und schreibt natürlich Berichte, damit es bei der korrupten EU auch noch eine vorläufige Zulassung erhält.
Eine übelsten Bestechungs Geschichten, die Zulassung von hoch gefährlichen Pharma Betrugs Müll, u.a. mit dem Münchner Professor, des Schwabinger Krankenhauses. wo man über Leichen ging, um auch in Europa eine vorläufige Zulassung zu erhalten, identisch mit dem TAMIFLU Betrug.
Alle Studien waren erneut gefälscht, nachdem alten Modell. Mit Entsetzen, mussten die Redakteure von Lancet, etc. diese gefälschte Studie für ungültig erklären, weil vollkommen gefälscht, als PR Instrument.
Umgekehrt wird gesagt, dass Remdesivir wirksam und ohne besondere Gefahr ist.
Das ist nicht wahr.
Remdesivir kann unter anderem schweres Nierenversagen (Dialyse, Nierentransplantation erforderlich), Leberversagen, genetische Mutation, Herzprobleme bis hin zum Herzstillstand verursachen [4]. Das ist die Wahrheit.
Aktiv dabei bei dem bezahlten Studien Betrug mit Menschenversuchen der übelsten Art: . Das ursprünglich gegen Ebola entwickelte US-Präparat namens Remdesivir werde in einer international angelegten Studie an rund 1000 Patienten in rund 50 Kliniken rund um die Welt erprobt, teilte Chefarzt Clemens Wendtner von der Klinik für Infektiologie in der München Klinik Schwabing mit
COVID-19 – Remdesivir: License to Kill. Hydroxychloroquine: Prohibition to Cure. By , July 17, 2020
[4] L’entreprise Gilead aurait-elle dissimulé la vraie toxicité du Veklury © (remdesivir)? , 8 juillet 2020, „Es scheint daher, dass wir auf der Grundlage der oben vorgelegten Beweise fest davon überzeugt sind, dass Veklury (Remdesivir) eine schädliche Droge ist und dass diese Beweise von Gilead verschwiegen wurden. Wir glauben, dass die Lobbyarbeit in den Medien und bestimmten Gesundheitsbehörden zur Diskreditierung von Hydroxychloroquin, insbesondere in Krankenhäusern, Velkury (Remdesivir) zur einzigen Lösung in dieser Situation machen sollte. “
LancetGate: “Scientific Corona Lies” and Big Pharma Corruption. Hydroxychloroquine versus Gilead’s Remdesivir
Minor updates and additions on July 6, 2020
Introduction
There is an ongoing battle to suppress Hydroxychloroquine (HCQ), a cheap and effective drug for the treatment of Covid-19. The campaign against HCQ is carried out through slanderous political statements, media smears, not to mention an authoritative peer reviewed “evaluation” published on May 22nd by The Lancet, which was based on fake figures and test trials.
The study was allegedly based on data analysis of 96,032 patients hospitalized with COVID-19 between Dec 20, 2019, and April 14, 2020 from 671 hospitals Worldwide. The database had been fabricated. The objective was to kill the Hydroxychloroquine (HCQ) cure on behalf of Big Pharma.
While The Lancetarticle was retracted, the media casually blamed “a tiny US based company” named Surgisphere whose employees included “a sci-fi writer and adult content model” for spreading “flawed data” (Guardian). This Chicago based outfit was accused of having misled both the WHO and national governments, inciting them to ban HCQ. None of those trial tests actually took place.
While the blame was placed on Surgisphere, the unspoken truth (which neither the scientific community nor the media have acknowledged) is that the study was coordinated by Harvard professor Mandeep Mehra under the auspices of Brigham and Women’s Hospital (BWH) which is a partner of the Harvard Medical School.
When the scam was revealed, Dr. Mandeep Mehra who holds the Harvey Distinguished Chair of Medicine at Brigham and Women’s Hospital apologized:
I have always performed my research in accordance with the highest ethical and professional guidelines. However, we can never forget the responsibility we have as researchers to scrupulously ensure that we rely on data sources that adhere to our high standards.
It is now clear to me that in my hope to contribute this research during a time of great need, I did not do enough to ensure that the data source was appropriate for this use. For that, and for all the disruptions – both directly and indirectly – I am truly sorry. (emphasis added)
Mandeep R. Mehra, MD, MSC (official statement on BWH website)
But that “truly sorry” note was just the tip of the iceberg. Why?
Studies on Gilead Science’s Remdesivir and Hydroxychloroquine (HCQ) Were Conducted Simultaneously by Brigham and Women’s Hospital (BWH)
While The Lancetreport (May 22, 2020) coordinated by Dr. Mandeep Mehra was intended “to kill” the legitimacy of HCQ as a cure of Covid-19, another important (related) study was being carried out (concurrently) at BWH pertaining to Remdesivir on behalf of Gilead Sciences Inc. Dr. Francisco Marty, a specialist inInfectious Disease and Associate Professor at Harvard Medical School was entrusted with coordination of the clinical trial tests of the antiviral medication Remdesivir under Brigham’s contract with Gilead Sciences Inc:
Brigham and Women’s Hospital began enrolling patients in two clinical trials for Gilead’s antiviral medication remdesivir. The Brigham is one of multiple clinical trial sites for a Gilead-initiated study of the drug in 600 participants with moderate coronavirus disease (COVID-19) and a Gilead-initiated study of 400 participants with severe COVID-19.
… If the results are promising, this could lead to FDA approval, and if they aren’t, it gives us critical information in the fight against COVID-19 and allows us to move on to other therapies.”
While Dr. Mandeep Mehra was not directly involved in the Gilead Remdesevir BWH study under the supervision of his colleague Dr. Francisco Marty, he nonetheless had contacts with Gilead Sciences Inc: “He participated in a conference sponsored by Gilead in early April 2020 as part of the Covid-19 debate” (France Soir, May 23, 2020)
What was the intent of his (failed) study? To undermine the legitimacy of Hydroxychloroquine?
According to France Soir, in a report published after The Lancet Retraction:
The often evasive answers produced by Dr Mandeep R. Mehra, … professor at Harvard Medical School, did not produce confidence, fueling doubt instead about the integrity of this retrospective study and its results. (France Soir, June 5, 2020)
Was Dr. Mandeep Mehra in conflict of interest? (That is a matter for BWH and the Harvard Medical School to decide upon).
Who are the Main Actors?
Dr. Anthony Fauci, advisor to Donald Trump, portrayed as “America’s top infectious disease expert” has played a key role in smearing the HCQ cure which had been approved years earlier by the CDC as well as providing legitimacy to Gilead’s Remdesivir.
Dr. Fauci has been the head of the National Institute of Allergy and Infectious Diseases (NIAID) since the Reagan administration. He is known to act as a mouthpiece for Big Pharma.
Dr. Fauci launched Remdesivir in late June (see details below). According to Fauci, Remdesevir is the “corona wonder drug” developed by Gilead Science Inc. It’s a $1.6 billion dollar bonanza.
Gilead Sciences Inc: History
Gilead Sciences Inc is a Multibillion dollar bio-pharmaceutical company which is now involved in developing and marketing Remdesivir. Gilead has a long history. It has the backing of major investment conglomerates including the Vanguard Group and Capital Research & Management Co, among others. It has developed ties with the US Government.
In 1999 Gilead Sciences Inc, developed Tamiflu (used as a treatment of seasonal influenza and bird flu). At the time, Gilead Sciences Inc was headed by Donald Rumsfeld (1997-2001), who later joined the George W. Bush administration as Secretary of Defense (2001-2006). Rumsfeld was responsible for coordinating the illegal and criminal wars on Afghanistan (2001) and Iraq (2003).
Rumsfeld maintained his links to Gilead Sciences Inc throughout his tenure as Secretary of Defense (2001-2006). According to CNN Money (2005): “The prospect of a bird flu outbreak … was very good news for Defense Secretary Donald Rumsfeld [who still owned Gilead stocks] and other politically connected investors in Gilead Sciences”.
Anthony Fauci has been in charge of the NIAID since 1984, using his position as “a go between” the US government and Big Pharma. During Rumsfeld’s tenure as Secretary of Defense, the budget allocated to bio-terrorism increased substantially, involving contracts with Big Pharma including Gilead Sciences Inc. Anthony Fauci considered that the money allocated to bio-terrorism in early 2002 would:
“accelerate our understanding of the biology and pathogenesis of microbes that can be used in attacks, and the biology of the microbes’ hosts — human beings and their immune systems. One result should be more effective vaccines with less toxicity.” (WPo report)
In 2008, Dr. Anthony Fauci was granted the Presidential Medal of Freedom by president George W. Bush “for his determined and aggressive efforts to help others live longer and healthier lives.”
The 2020 Gilead Sciences Inc Remdesivir Project
We will be focussing on key documents (and events)
Chronology
February 21: Initial Release pertaining to NIH-NIAID Remdesivir placebo test trial
April 10: The Gilead Sciences Inc study published in the NEJM on the “Compassionate Use of Remdesivir”
April 29: NIH Release: Study on Remdesivir (Report published on May 22 in NEJM)
May 22, The BWH-Harvard Study on Hydroxychloroquine coordinated by Dr. Mandeep Mehra published in The Lancet
May 22, Remdesivir for the Treatment of Covid-19 — Preliminary Report National Institute of Allergy and Infectious Diseases, National Institutes of Health, New England Journal of Medicine, (NEJM)
June 5: The (fake) Lancet Report (May 22) on HCQ is Retracted.
June 29, Fauci announcement. The $1.6 Billion Remdevisir HHS Agreement with Gilead Sciences Inc
April 10: The Gilead Sciences Inc. study published in the NEJM on the “Compassionate Use of Remdesivir”
A Gilead sponsored report was published in New England Journal of Medicine in an article entitled “Compassionate Use of Remdesivir for Patients with Severe Covid-19” . It was co-authored by an impressive list of 56 distinguished medical doctors and scientists, many of whom were recipients of consulting fees from Gilead Sciences Inc.
Gilead Sciences Inc. funded the study which included several staff members as co-authors.
The testing included a total of 61 patients [who] received at least one dose of remdesivir on or before March 7, 2020; 8 of these patients were excluded because of missing postbaseline information (7 patients) and an erroneous remdesivir start date (1 patient) … Of the 53 remaining patients included in this analysis, 40 (75%) received the full 10-day course of remdesivir, 10 (19%) received 5 to 9 days of treatment, and 3 (6%) fewer than 5 days of treatment.
The NEJM article states that “Gilead Sciences Inc began accepting requests from clinicians for compassionate use of remdesivir on January 25, 2020”. From whom, From Where? According to the WHO (January 30, 2020) there were 82 cases in 18 countries outside China of which 5 were in the US, 5 in France and 3 in Canada.
Several prominent physicians and scientists have cast doubt on the Compassionate Use of Remdesivir study conducted by Gilead, focussing on the small size of the trial. Ironically, the number of patients in the test is less that the number of co-authors: “53 patients” versus “56 co-authors”
Below we provide excerpts of scientific statements on the Gilead NEJM project (Science Media Centre emphasis added) published immediately following the release of the NEJM article:
“‘Compassionate use’ is better described as using an unlicensed therapy to treat a patient because there are no other treatments available. Research based on this kind of use should be treated with extreme caution because there is no control group or randomisation, which are some of the hallmarks of good practice in clinical trials. Prof Duncan Richard, Clinical Therapeutics, University of Oxford.
“It is critical not to over-interpret this study. Most importantly, it is impossible to know the outcome for this relatively small group of patients had they not received remdesivir. Dr Stephen Griffin, Associate Professor, School of Medicine, University of Leeds.
“The research is interesting but doesn’t prove anything at this point: the data are from a small and uncontrolled study. Simon Maxwell, Professor of Clinical Pharmacology and Prescribing, University of Edinburgh.
“The data from this paper are almost uninterpretable. It is very surprising, perhaps even unethical, that the New England Journal of Medicine has published it. It would be more appropriate to publish the data on the website of the pharmaceutical company that has sponsored and written up the study. At least Gilead have been clear that this has not been done in the way that a high quality scientific paper would be written. Prof Stephen Evans, Professor of Pharmacoepidemiology, London School of Hygiene & Tropical Medicine.
“It’s very hard to draw useful conclusions from uncontrolled studies like this particularly with a new disease where we really don’t know what to expect and with wide variations in outcomes between places and over time. One really has to question the ethics of failing to do randomisation – this study really represents more than anything else, a missed opportunity.” Prof Adam Finn, Professor of Paediatrics, University of Bristol.
To review the complete document of Science Media Centre pertaining to expert assessments click here
April 29: The National Institutes of Health (NIH) Study on Remdevisir.
On April 29th following the publication of the Gilead Sciences Inc Study in the NEJM on April 10, a press release of the National Institutes of Health (NIH) on Remdevisir was released. The full document was published on May 22, by the NEJM under the title:
Remdesivir for the Treatment of Covid-19 — Preliminary Report (NEJM)
The study had been initiated on February 21, 2020. The title of the April 29 Press Release was:
“Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery”
It’s a government sponsored report which includes preliminary data from a randomized trial involving 1063 hospitalized patients. The results of the trial labelled Adaptive COVID-19 Treatment Trial (ACTT) are preliminary, conducted under the helm of Dr. Fauci’s National Institute of Allergy and Infectious Diseases (NIAID):
……………………………………
Gilead Sciences Inc: History
Gilead Sciences Inc is a Multibillion dollar bio-pharmaceutical company which is now involved in developing and marketing Remdesivir. Gilead has a long history. It has the backing of major investment conglomerates including the Vanguard Group and Capital Research & Management Co, among others. It has developed ties with the US Government.
In 1999 Gilead Sciences Inc, developed Tamiflu (used as a treatment of seasonal influenza and bird flu). At the time, Gilead Sciences Inc was headed by Donald Rumsfeld (1997-2001), who later joined the George W. Bush administration as Secretary of Defense (2001-2006). Rumsfeld was responsible for coordinating the illegal and criminal wars on Afghanistan (2001) and Iraq (2003).
Rumsfeld maintained his links to Gilead Sciences Inc throughout his tenure as Secretary of Defense (2001-2006). According to CNN Money (2005): “The prospect of a bird flu outbreak … was very good news for Defense Secretary Donald Rumsfeld [who still owned Gilead stocks] and other politically connected investors in Gilead Sciences”.
Anthony Fauci has been in charge of the NIAID since 1984, using his position as “a go between” the US government and Big Pharma. During Rumsfeld’s tenure as Secretary of Defense, the budget allocated to bio-terrorism increased substantially, involving contracts with Big Pharma including Gilead Sciences Inc. Anthony Fauci considered that the money allocated to bio-terrorism in early 2002 would:
“accelerate our understanding of the biology and pathogenesis of microbes that can be used in attacks, and the biology of the microbes’ hosts — human beings and their immune systems. One result should be more effective vaccines with less toxicity.” (WPo report)
In 2008, Dr. Anthony Fauci was granted the Presidential Medal of Freedom by president George W. Bush “for his determined and aggressive efforts to help others live longer and healthier lives.”
The 2020 Gilead Sciences Inc Remdesivir Project
………………………………………………………………………………………….
Retraction by France Soir
The fraud concerning the Lancet Report was revealed in early June. France Soirin a subsequent article (June 5, 2020) points to the Boston Connection: La connexion de Boston, namely the insiduous relationship between Gilead Sciences Inc and Professor Mehra, Harvard Medical School as well as the two related Boston based hospitals involved.
……………………………………………
“Both hospitals are conducting clinical trials of remdesivir.”
MGH has joined what the National Institute of Health (NIH) describe as the first clinical trial in the United States of an experimental treatment for COVID-19, sponsored by the National Institute of Allergy and Infectious Diseases, part of NIH. MGH is currently the only hospital in New England to participate in this trial, according to a list of sites shared by the hospital.
” It’s a gigantic undertaking, with patients registered in some 50 sites across the country, getting better.
“The NIH trial, which can be adapted to evaluate other treatments, aims to determine whether the drug relieves the respiratory problems and other symptoms of COVID-19, helping patients leave hospital earlier.**
As a reminder, the NIAID/NIH is led by Antony Fauci, a staunch opponent of HCQ.
Coincidence, probably.
“At the Brigham, two additional trials initiated by Gilead, the drug developer, will determine whether it alleviates symptoms in patients with moderate to severe illness over five- and ten-days courses. These trials will also be randomized, but not placebo controlled, and will include 1,000 patients at sites worldwide. Those patients, noted Francisco Marty, MD, Brigham physician and study co-investigator, will likely be recruited at an unsettlingly rapid clip.”
As a result, the first major clinical trials on remdesivir launched on March 20, whose results are highly important for Gilead, are being led by the MGH and BWH in Boston, precisely where Dr. Mehra, the main author of the May 22nd HCQ trial, is practising.
Small world! Coincidence, again, probably.
Dr. Marty at BWH expected to have results two months later. Indeed, in recent days, several US media outlets have reported Gilead’s announcements of positive results from the remdesivir clinical trials in Boston.:
“Encouraging results from a new study published Wednesday on remdesivir for the treatment of patients with COVID-19.**
Brigham and Dr. Francisco Marty worked on this study, and he says the results show that there is no major difference between treating a patient with a five-day versus a 10-day regimen.
…”Gilead Announces Results of Phase 3 Remdesivir Trial in Patients with Moderate COVID-19
– One study shows that the 5-day treatment of remdesivir resulted in significantly greater clinical improvement compared to treatment with the standard of care alone
– The data come on top of the body of evidence from previous studies demonstrating the benefits of remdesivir in hospitalized patients with IDVOC-19
“We now have three randomized controlled trials demonstrating that remdesivir improved clinical outcomes by several different measures,” Gilead plans to submit the complete data for publication in a peer-reviewed journal in the coming weeks.
These results announced by Gilead a few days after the May 22 publication of the study in the Lancet demolishing HCQ, a study whose main author is Dr. Mehra, are probably again a coincidence.
So many coincidences adds up to coincidences? Really ?
Major media outlets in multiple countries ran with the headlines trumpeting that Moderna’s Covid-19 vaccine “shows promising early results” and has presented “encouraging early signs” because of its purported ability to produce Covid-19 antibodies in humans. In addition, these media reports failed to raise other simple yet necessary questions such as how a sample size of only eight people can translate into scientific findings of any real significance without further testing involving larger sample sizes. They also failed to note that the study in question isnot even finished as a U.S. government press release noted that the findings in question are merely “interim results.” In addition, the study is being led by the U.S.’ National Institute of Allergy and Infectious Diseases (NIAID), itself headed by Dr. Anthony Fauci, who is a key figure in the U.S. government’s coronavirus response.
Though it is unclear if these “encouraging early signs” will be replicated in future tests of larger samples that are actually designed to test the vaccine’s effectiveness, the news is surely welcome to Moderna, given that their past mRNA vaccines failed to produce hardly any immune response at all, explaining why the company has never brought an mRNA vaccine to market in its entire history as a company.
However, since at least last fall, Moderna has sought to resolve this issue by adding “nanoparticles” to its mRNA vaccine, a modification financed by the Pentagon’s Defense Advanced Research Projects Agency (DARPA). Moderna is a “strategic ally” of DARPA and has received millions from DARPA and the Bill and Melinda Gates Foundation several years prior to the current coronavirus crisis. DARPA’s plans for nanoparticles and nanotechnology and their potentially Orwellian applications were the subject of a recent The Last American Vagabond report.
Uralte Pentagon Forschung, von DARPA, und geforscht, wurde vor der erfundenen Corona Pandemie.
Die Suche nach Corona-Impfstoffen nimmt Fahrt auf
Moderna und Johnson & Johnson starten bald mit großen klinischen Studien. Auch ihre Produktionskapazitäten fahren die Pharmakonzerne bereits hoch.
Staatsmilliarden als Antrieb
Wie die Pharmabosse von der Krise profitieren
![07.05.2018, Berlin: Katrin Suder (links), ehemalige StaatssekretŠrin im Bundesministerium der Verteidigung, wird von Ursula von der Leyen (CDU), Verteidigungsministerin, im Bundesverteidigungsministerium am Bendlerblock mit einer feierlichen Serenade verabschiedet. Die feierliche Serenade ist eine Ehrenbekundung fŸr Persšnlichkeiten, die sich in besonderem Ma§e um die Bundeswehr verdient gemacht haben. Die frŸhere Unternehmensberaterin Suder, die auf eigenen Wunsch aus dem StaatssekretŠrsamt ausgeschieden ist, war fŸr die Abteilungen Planung, AusrŸstung und Cyber/Informationstechnik zustŠndig. Foto: Bernd von Jutrczenka/dpa [ Rechtehinweis: (c) dpa ]](https://geopolitiker.files.wordpress.com/2019/11/karin-suder-ursula.jpg?w=405&resize=405%2C229&h=229#038;h=229 "Verabschiedung von StaatssekretŠrin Katrin Suder")
Geopolitiker's Blog 
Neueste Kommentare